President and CEO Jake Leach took over the corner office in January. In the months that have followed, highlights include the unveiling of the next-generation G8 sensor system, the launch of the Flex sensor platform outside the U.S. and the acquisition of Nutrisense, a wellness tracking company, alongside app updates to the Stelo over-the-counter CGM.
Finally, last weekend at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans, the company shared clinical findings further demonstrating the benefits of its CGM technology.
Leach spoke with Drug Delivery Business News during ADA 2026 outlining the company’s recent milestones and what is set to come.
“The use of CGM is expanding rapidly around the world,” Leach said. “Within diabetes, we now have Grade A evidence across the whole spectrum of patients about the improvements in metabolic health that are seen when using CGM. We’re going to continue to drive that across pre-diabetes and health, wellness and longevity.”
On the Nutrisense deal
With its acquisition of Nutrisense, Dexcom plans to further expand its ability to support users beyond glucose data alone.
Nutrisense’s offerings enable Dexcom to incorporate access to registered dietitians, personalized nutrition guidance and behavior-change support. It offers 24/7 glucose data and expert coaching designed to help cut cravings, boost energy and lose weight.
“It’s based on certified, highly experienced nutritionists that are guiding people on their journey through using CGM,” Leach explained. “Then, the nutrition coaching component of it helps get them a better outcome.”
The company offers metabolism-tracking technology to help users understand what’s behind their exhaustion, weight and anxiety. It also features AI capabilities to track patterns between every session and provide information and updates to dietitians.
“The really exciting thing is that it drives a lot of engagement early, when someone is starting up on a CGM,” Leach said. “We feel that Stelo and all of our products could benefit from some engagement up front for the user around the nutrition. I think that really drives user engagement, then higher retention.”
The company has long held a partnership with Nutrisense and Leach said it made sense to add the company’s offerings to its own portfolio.
‘We really feel that this is going to be a great partnership,” he said. “We’ve been partners for a while and now feel like it’s the right time to make them part of the Dexcom team and integrate that technology directly into our own products.”
On the next-generation Dexcom G8
The next-generation G8 builds on the existing G7 with a 50% smaller form factor and advanced sensing capabilities. It will adapt to the physiological variability of each user and has additional built-in technology based on a new silicon chip design and algorithm.
With the new technology, G8 can measure additional signals from the sensor, going beyond glucose, allowing it to adapt to physiologic changes and reduce outliers in real-time and eliminate them. The technology combines traditional factory calibration with adapting capabilities for every user.
Additionally, with the recent rollout of the G7 15 Day CGM system, G8’s 15-day wear time is the baseline for all sensors moving forward.
Leach said he’s most excited about the glucose performance of G8.
“Over time, we’ve continuously made the products more accurate, more reliable and we see that reflected in the use of the products,” he said.
For G8, the company reduced its size by redesigning all of the electronics, including a smaller battery. It also added alternate analyte sensing capabilities, as multi-analyte capabilities look set to bring a new paradigm to biosensing technology. Leach mentioned potassium, ketones and lactate sensing as areas under development for implementation onto the G8 platform.
Enhanced sensing capabilities come through self-adapting technology, responding to glucose and adjusting sensor signals to make the sensor even more accurate and reducing the number of outlier readings.
“We’ll be ready to go when it happens,” Leach said. “We’re incredibly excited and ready to get this thing out there that’s going to be a real benefit for customers.”
On the company’s continued type 2 diabetes push
Dexcom’s data at ADA 2026 came from the CONNECT study, which evaluated the current-generation G7 in people with type 2 diabetes not using insulin. It compared this population to a routine care control group using self-monitoring of blood glucose.
The company said outcomes demonstrated that G7 use leads to clinically and statistically significant A1C reduction and improvement in glucose control in people with type 2 diabetes not using insulin.
CONNECT demonstrated clinically significant benefit for all adult type 2 non-insulin users regardless of age, gender, ethnicity, baseline A1C, body mass index, education level, income and insurance coverage. The study also showed an additional clinically significant A1C reduction with G7 alongside various combinations of current standard of care diabetes medication. Those include metformin, GLP-1s and SGLT2s.
“I think that is a very powerful clinical data set that we’re going to use to drive access around the globe,” Leach said.
The results come as Dexcom pushes to bring CGM to more people with diabetes, especially by potentially securing Medicare coverage for the use of the technology in that population.
“Our goal is to ensure that everybody with diabetes has access to CGM,” Leach said. “We, so we have lots of work to do there. … It’s a complex healthcare environment out there around the world, and one of the really important tools that we have to drive that type of access is the evidence, like the CONNECT study, that shows just how impactful the technology can be, both from a health perspective, but also an economic perspective.”
What’s next?
Leach said the company remains on the cusp of Medicare coverage for all people with diabetes. Currently, Medicare only covers CGM for those who have diabetes and use insulin. Leach said that constitutes about a third of those who have diabetes.
“You’ve got two thirds of people out there on Medicare that don’t have access to CGM yet,” Leach said. “They have diabetes and could really benefit [from CGM], so we’re looking forward to a decision there soon.”
The company has started to pick up coverage form commercial payers, recently adding about another million people covered with a positive coverage decision from a large PBM. Leach said Dexcom currently has about 50% coverage across commercial insurance.
“Our goal is to get everybody access, because everybody can benefit,” he said.
Across the company’s widening portfolio, with new CGMs, over-the-counter options with Stelo, wellness capabilities through acquisitions like Nutrisense and partnerships with Oura, Dexcom continues to look to bring CGM and biosensing technology to those who can benefit from it.
“We have seen a lot of people benefiting from CGM and we’ll continue to drive it,” Leach said. “We’ll continue to enhance it.”
